Skip to main content
Year archive

Lupin Ltd — 2022 filings

All 316 regulatory filings released by Lupin Ltd (LUPIN) in 2022, sourced directly from the official regulator.

316 Filings
2022 Period
2022 filings (316)
Filing Released Lang
ESOP/ESOS/ESPS
Regulatory Filings
2022-12-29 English
Disclosure pursuant to Grant of 9450 Stock Options under Lupin Subsidiary Companies Employees Stock Option Plan.
Regulatory Filings
2022-12-29 English
Resignation
Board/Management Information
2022-12-22 English
Ms. Christine Mundkur (DIN: 08408494), Independent Director, Lupin Limited, will be stepping down from the Board of Directors of the Company, effective January 1, 2023.
Regulatory Filings
2022-12-22 English
Lupin Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Four Lots of Quinapril Tablets due to potential presence of N-Nitroso-Quinapril Impurity.
Regulatory Filings
2022-12-22 English
Press Release
Regulatory Filings
2022-12-22 English
Press Release
Regulatory Filings
2022-12-21 English
Lupin Diagnostics Expands its Footprint in Central India; Launches Regional Reference Laboratory in Indore.
Regulatory Filings
2022-12-21 English
Lupin Receives Approval from U.S. FDA for Brivaracetam Tablets.
Regulatory Filings
2022-12-21 English
Press Release
Regulatory Filings
2022-12-21 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2022-12-17 English
Disclosure pursuant to grant of 467312 stock options to the employees of Lupin Limited and its subsidiaries.
Share Issue/Capital Change
2022-12-17 English
Lupin Launches Authorized Generic Version of PENNSAID® 2% w/w in the United States.
Regulatory Filings
2022-12-09 English
Press Release
Regulatory Filings
2022-12-09 English
Press Release
Board/Management Information
2022-12-08 English
Lupin Appoints Spiro Gavaris as President of U.S. Generics Business.
Board/Management Information
2022-12-08 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-12-08 English
Disclosure pursuant to allotment of 26613 shares under ESOP.
Regulatory Filings
2022-12-08 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-12-08 English
Lupin Launches Rufinamide Tablets USP in the United States.
Regulatory Filings
2022-12-05 English
Press Release
Regulatory Filings
2022-12-05 English
Intimation about loss of share certificate by shareholder.
Regulatory Filings
2022-11-29 English
Loss of share certificate
Regulatory Filings
2022-11-29 English
Lupin Launches Formoterol Fumarate Inhalation Solution in the United States.
Regulatory Filings
2022-11-29 English
Press Release
Regulatory Filings
2022-11-29 English
Lupin''s Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch Health.
Capital/Financing Update
2022-11-28 English
Press Release
Capital/Financing Update
2022-11-28 English
U.S. FDA Inspection of the Company''s Mandideep Unit-1 facility.
Regulatory Filings
2022-11-24 English
General updates
Regulatory Filings
2022-11-24 English
U.S. FDA Inspection of the Company's Mandideep Unit-1 facility.
Regulatory Filings
2022-11-24 English
General updates
Regulatory Filings
2022-11-24 English
Disclosure of Related Party Transactions for the half year ended September 30, 2022
Regulatory Filings
2022-11-23 English
Related Party Transaction
Regulatory Filings
2022-11-23 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-11-22 English
Disclosure pursuant to Grant of 177781 stock options under Employees Stock Option Plans.
Regulatory Filings
2022-11-22 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-11-21 English
Disclosure pursuant to allotment of 42114 shares under ESOP.
Regulatory Filings
2022-11-21 English
Lupin Signs MoU with the Government of Rajasthan to strengthen Healthcare system.
Regulatory Filings
2022-11-21 English
Press Release
Regulatory Filings
2022-11-21 English
Transcript of Q2 FY2023 Earnings Conference Call.
Call Transcript
2022-11-16 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Call Transcript
2022-11-16 English
Loss of share certificate
Regulatory Filings
2022-11-15 English
Intimation of loss of share certificate by shareholders.
Regulatory Filings
2022-11-15 English
Intimation regarding issuance of duplicate Share certificate.
Regulatory Filings
2022-11-11 English
Loss of share certificate
Regulatory Filings
2022-11-11 English
Audio/Video recording of the Earnings Call - Q2 FY 2022-23.
Regulatory Filings
2022-11-10 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-11-10 English
News Verification
Regulatory Filings
2022-11-10 English
Investor Presentation Q2 FY23.
Investor Presentation
2022-11-10 English
Investor Presentation
Investor Presentation
2022-11-10 English
Lupin Q2 FY2023 Results.
Interim / Quarterly Report Q2 2023
2022-11-09 English
Press Release
Interim / Quarterly Report Q2 2023
2022-11-09 English
Unaudited standalone and consolidated financial results along with Limited Review Reports for the quarter and half-year ended September 30, 2022.
Regulatory Filings
2022-11-09 English
Outcome of Board Meeting
Regulatory Filings
2022-11-09 English
Press Release
Regulatory Filings
2022-11-08 English
Lupin Receives Tentative Approval from U.S. FDA for Doxycycline Capsules.
Regulatory Filings
2022-11-08 English
Press Release
Regulatory Filings
2022-11-04 English
Lupin Receives Tentative Approval from U.S. FDA for Drospirenone Tablets.
Regulatory Filings
2022-11-04 English
The Exchange had sought clarification from Lupin Ltd with respect to news article appearing on https://www.business-standard.com dated November 02, 2022 (Link:https://www.business-standard.com/article
Regulatory Filings
2022-11-04 English
General updates
Regulatory Filings
2022-10-30 English
U.S. FDA Inspection of the Company's Nagpur Unit-2 injectable manufacturing facility.
Regulatory Filings
2022-10-30 English
Earnings Call for Quarter - II, FY 2023 is scheduled on Thursday, November 10, 2022 at 16.00 hrs (IST).
Regulatory Filings
2022-10-28 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-10-28 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 ,inter alia, to consider and approve the unaudited financial results of the ....
Regulatory Filings
2022-10-27 English
Board Meeting — Financial results/Other business matters
Regulatory Filings
2022-10-27 English
Press Release
Regulatory Filings
2022-10-20 English
Lupin Launches Paliperidone Extended-Release Tablets in the United States.
Regulatory Filings
2022-10-20 English
Press Release
Capital/Financing Update
2022-10-20 English
Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion.
Capital/Financing Update
2022-10-20 English
General updates
Regulatory Filings
2022-10-19 English
Update on the Company's Biotech manufacturing facility.
Regulatory Filings
2022-10-19 English
Intimation regarding loss of Share Certificates by Shareholder.
Regulatory Filings
2022-10-19 English
Loss of share certificate
Regulatory Filings
2022-10-19 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-10-13 English
Disclosure pursuant to allotment of 17306 shares under ESOP.
Regulatory Filings
2022-10-13 English
Loss of share certificate
Regulatory Filings
2022-10-13 English
Intimation of Loss of Share Certificate by Shareholder.
Regulatory Filings
2022-10-13 English
Dr. Kamal K. Sharma (DIN: 00209430), Non-Executive Vice Chairman of the Company, will be stepping down from the Board of Directors of the Company with effect from October 14, 2022.
Board/Management Information
2022-10-07 English
Cessation
Board/Management Information
2022-10-07 English
Loss of share certificate
Regulatory Filings
2022-10-07 English
Intimation of Loss of Share Certificate by Shareholder.
Regulatory Filings
2022-10-07 English
Press Release
Regulatory Filings
2022-10-07 English
Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment.
Capital/Financing Update
2022-10-07 English
Press Release
Board/Management Information
2022-10-06 English
Lupin Appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer.
Board/Management Information
2022-10-06 English
Loss of share certificate
Regulatory Filings
2022-10-04 English
Intimation of Loss of Share Certificate by Shareholder.
Regulatory Filings
2022-10-04 English
General updates
Regulatory Filings
2022-10-04 English
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2022.
Regulatory Filings
2022-10-04 English
Lupin Receives Approval from U.S. FDA for Darunavir Tablets.
Regulatory Filings
2022-10-04 English
Press Release
Regulatory Filings
2022-10-04 English
Press Release
Regulatory Filings
2022-10-01 English
Lupin Life announces association with Vikram Vedha as official energy partner with its Be One health and wellness supplement.
Regulatory Filings
2022-10-01 English
Press Release
Regulatory Filings
2022-10-01 English
Lupin gets EIR from U.S. FDA for its Ankleshwar Manufacturing Facility.
Regulatory Filings
2022-10-01 English
Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets.
Regulatory Filings
2022-09-29 English
Press Release
Regulatory Filings
2022-09-29 English
Press Release
Regulatory Filings
2022-09-29 English
Lupin Launches Sildenafil for Oral Suspension in the United States.
Regulatory Filings
2022-09-29 English
Company has received a warning letter from the U.S. FDA for the Company's Tarapur, Maharashtra (India) facility.
Regulatory Filings
2022-09-29 English
General updates
Regulatory Filings
2022-09-29 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-09-26 English
Disclosure pursuant to allotment of 4271 shares under Lupin ESOP.
Regulatory Filings
2022-09-26 English
Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w.
Regulatory Filings
2022-09-22 English
Press Release
Regulatory Filings
2022-09-22 English
Loss of share certificate
Regulatory Filings
2022-09-22 English
Intimation of Loss of Share Certificate by Shareholders.
Regulatory Filings
2022-09-22 English
Lupin Receives Health Canada Approval for Rymti® (biosimilar Etanercept).
Regulatory Filings
2022-09-13 English
Press Release
Regulatory Filings
2022-09-13 English
Press Release
Regulatory Filings
2022-09-09 English
Lupin Launches Generic Suprep® Bowel Prep Kit in the United States.
Regulatory Filings
2022-09-09 English
Press Release
Regulatory Filings
2022-09-07 English
Lupin and DKSH Sign an Exclusive Licensing and Supply Agreement to Market Five Biosimilar Candidates in the Philippines.
Regulatory Filings
2022-09-07 English
Lupin Receives Tentative Approval from U.S. FDA for Dasatinib Tablets.
Regulatory Filings
2022-08-29 English
Press Release
Regulatory Filings
2022-08-29 English
Press Release
Regulatory Filings
2022-08-26 English
Lupin Launches Desvenlafaxine Extended-Release Tablets in the United States.
Regulatory Filings
2022-08-26 English
Press Release
Regulatory Filings
2022-08-26 English
Lupin Announces UK MHRA Approval of Lutio® (Tiotropium bromide inhalation powder) for Treatment of COPD.
Regulatory Filings
2022-08-26 English
Press Release
Capital/Financing Update
2022-08-25 English
Lupin and I'rom Enter into an Exclusive Licensing Agreement for Denosumab biosimilar for Japan.
Regulatory Filings
2022-08-25 English
Acquisition
Capital/Financing Update
2022-08-24 English
Lupin Limited has entered into Deed of Assignment with Boehringer Ingelheim International GmbH for the acquisition of brands Ondero and Ondero - Met (including trademark rights associated ....
Capital/Financing Update
2022-08-24 English
Lupin Receives Approval from U.S. FDA for Formoterol Fumarate Inhalation Solution.
Regulatory Filings
2022-08-24 English
Press Release
Regulatory Filings
2022-08-24 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-08-24 English
Disclosure pursuant to Allotment of 30113 shares under ESOP.
Regulatory Filings
2022-08-24 English
Loss of share certificate
Regulatory Filings
2022-08-22 English
Intimation regarding Loss of Share Certificate by Shareholders.
Regulatory Filings
2022-08-22 English
Lupin Receives Approval from U.S. FDA for Rufinamide Tablets USP.
Regulatory Filings
2022-08-18 English
Press Release
Regulatory Filings
2022-08-18 English
Business Responsibility & Sustainability Report for the year ended March 31, 2022.
Environmental & Social Information
2022-08-16 English
Lupin Receives Approval from U.S. FDA for Meclizine Hydrochloride Tablets USP.
Regulatory Filings
2022-08-12 English
Press Release
Regulatory Filings
2022-08-12 English
Loss of share certificate
Regulatory Filings
2022-08-10 English
Intimation regarding issuance Duplicate share certificate.
Regulatory Filings
2022-08-10 English
Loss of share certificate
Regulatory Filings
2022-08-09 English
Intimation regarding loss of Share certificate by shareholder.
Regulatory Filings
2022-08-09 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-08-09 English
Transcript of the Q1 FY2023 Earnings Conference Call held on Thursday, August 4, 2022.
Regulatory Filings
2022-08-09 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-08-04 English
Audio/Video recording of the Earnings Call - Q1 FY 2023.
Regulatory Filings
2022-08-04 English
Annual General Meeting
Regulatory Filings
2022-08-04 English
Scrutinizer''s Report for declaration of voting results at the Fortieth Annual General Meeting of the Company, held on Wednesday, August 3, 2022, at 4.00 p.m. (IST) through Video Conferencing/Other .
Regulatory Filings
2022-08-04 English
Disclosure pursuant to Loss of Share Certificate by Shareholders.
Regulatory Filings
2022-08-04 English
Loss of share certificate
Regulatory Filings
2022-08-04 English
Investor Presentation
Regulatory Filings
2022-08-04 English
Investor Presentation Q1 FY23
Regulatory Filings
2022-08-04 English
Lupin Q1 FY2023 Results.
Regulatory Filings
2022-08-03 English
Press Release
Regulatory Filings
2022-08-03 English
Outcome of Board Meeting
Regulatory Filings
2022-08-03 English
Unaudited standalone and consolidated financial results along with Limited Review Reports for the quarter ended June 30, 2022.
Regulatory Filings
2022-08-03 English
Proceedings at the 40th Annual General Meeting held on Wednesday, August 3, 2022.
Regulatory Filings
2022-08-03 English
Annual General Meeting
Regulatory Filings
2022-08-03 English
Press Release
Regulatory Filings
2022-07-25 English
Lupin Receives Approval from U.S. FDA for Azilsartan Medoxomil Tablets.
Regulatory Filings
2022-07-25 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-07-25 English
Disclosure pursuant to Allotment of 16772 shares under ESOP.
Regulatory Filings
2022-07-25 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-07-20 English
Intimation regarding grant of Stock Options.
Regulatory Filings
2022-07-20 English
Earnings Call for Quarter I, FY 2023 scheduled on Thursday, August 4, 2022 at 17:00 hrs (IST).
Regulatory Filings
2022-07-20 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-07-20 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2022 ,inter alia, to consider and approve the unaudited financial results of the ....
Regulatory Filings
2022-07-20 English
Board Meeting — Financial results/Other business matters
Regulatory Filings
2022-07-20 English
Lupin Diagnostics Launches its First Reference Laboratory in Ranchi.
Regulatory Filings
2022-07-19 English
Press Release
Regulatory Filings
2022-07-19 English
Business Responsibility & Sustainability Report (BRSR)
Regulatory Filings
2022-07-15 English
Submission of the Integrated Report of the Company for the year ended March 31, 2022 along with the Notice dated May 18, 2022, convening the Fortieth Annual General Meeting of the Company, ....
Regulatory Filings
2022-07-12 English
Press Release
Regulatory Filings
2022-07-07 English
Lupin's Somerset Manufacturing Plant Receives EIR from US FDA.
Regulatory Filings
2022-07-07 English
Record Date
AGM Information
2022-07-06 English
Disclosure under Regulations 42 and 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the Record date for the purpose of ascertaining the shareholders ....
Regulatory Filings
2022-07-05 English
Intimation regarding Annual General Meeting of Lupin Limited on August 3, 2022.
Regulatory Filings
2022-07-05 English
Annual General Meeting
Regulatory Filings
2022-07-05 English
Dividend
Regulatory Filings
2022-07-05 English
Certificate pursuant to Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended at June 30, 2022.
Regulatory Filings
2022-07-04 English
General updates
Regulatory Filings
2022-07-04 English
Press Release
Regulatory Filings
2022-06-30 English
Lupin Receives Approval from U.S. FDA for Paliperidone Extended-Release Tablets.
Regulatory Filings
2022-06-30 English
Secretarial Compliance Report for the year ended March 31, 2022.
Regulatory Filings
2022-06-28 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-06-27 English
Disclosure pursuant to allotment of 70724 shares under ESOP.
Regulatory Filings
2022-06-27 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification
2022-06-18 English
Disclosure under SEBI Takeover Regulations
Director's Dealing
2022-06-18 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings
2022-06-17 English
Loss of share certificate
Regulatory Filings
2022-06-17 English
Press Release
Regulatory Filings
2022-06-15 English
Lupin Diagnostics Launches its First Regional Reference Laboratory in Patna.
Regulatory Filings
2022-06-15 English
Loss of share certificate
Regulatory Filings
2022-06-10 English
Disclosure pursuant to loss of share certificate by the shareholder(s).
Regulatory Filings
2022-06-10 English
Press Release
Regulatory Filings
2022-06-08 English
Lupin Receives Tentative Approval from U.S. FDA for Ivacaftor Tablets.
Regulatory Filings
2022-06-08 English
Disclosure of Related Party Transactions for the half-year ended March 31, 2022.
Regulatory Filings
2022-06-02 English
Related Party Transaction
Regulatory Filings
2022-06-02 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Lupin Investments Pvt Ltd
Regulatory Filings
2022-05-31 English
Disclosure pursuant to allotment of 49499 shares under ESOP.
Regulatory Filings
2022-05-26 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-05-26 English
Transcript of Q4 FY2022 Investor Meet/Earnings Conference Call.
Regulatory Filings
2022-05-25 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-05-25 English
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
Regulatory Filings
2022-05-21 English
Audio/Video recording of the Investor Presentation FY 2021-22.
Investor Presentation
2022-05-19 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-05-19 English
Investor Presentation FY 2021-22.
Regulatory Filings
2022-05-19 English
Investor Presentation
Regulatory Filings
2022-05-19 English
Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 18, 2022, inter alia, hasrecommended dividend @200% i.e.Rs. 4/- per equity share of ....
Regulatory Filings
2022-05-19 English
Lupin FY2022 Results.
Regulatory Filings
2022-05-18 English
Press Release
Regulatory Filings
2022-05-18 English
Financial Result Updates
Regulatory Filings
2022-05-18 English
Audited Financial Statements for the quarter and year ended March 31, 2022.
Regulatory Filings
2022-05-18 English
FY 2022 Investors meet is scheduled on Thursday, May 19, 2022 at 15:30 hrs (IST).
Regulatory Filings
2022-05-11 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-05-11 English
Lupin Receives Approval from U.S. FDA for Iloperidone Tablets.
Regulatory Filings
2022-05-06 English
Press Release
Regulatory Filings
2022-05-06 English
Lupin Receives Approval from U.S. FDA for Pregabalin Capsules.
Regulatory Filings
2022-05-06 English
Press Release
Regulatory Filings
2022-05-06 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2022 ,inter alia, to consider and approve the audited standalone and consolidated ....
Regulatory Filings
2022-05-03 English
Board Meeting — Dividend/Financial results/Other business matters
Regulatory Filings
2022-05-03 English
Press Release
Regulatory Filings
2022-04-29 English
Lupin Launches its Reference Laboratory in Guwahati, Assam.
Regulatory Filings
2022-04-29 English
Lupin Appoints Diana Amador-Toro as Senior Vice President, Global Compliance.
Regulatory Filings
2022-04-27 English
Press Release
Regulatory Filings
2022-04-27 English
Lupin and Yabao Announce Strategic Partnership in China.
Regulatory Filings
2022-04-27 English
Press Release
Regulatory Filings
2022-04-27 English
ESOP/ESPS/SBEB Scheme
Share Issue/Capital Change
2022-04-26 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-04-26 English
Intimation of grant of 975 stock options under SESOP.
Regulatory Filings
2022-04-26 English
Intimation of Allotment of 28174 shares under ESOP.
Regulatory Filings
2022-04-26 English
Loss of share certificate
Regulatory Filings
2022-04-22 English
Intimation of issuance of duplicate share certificate.
Regulatory Filings
2022-04-22 English
Certificate under Regulation 40 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended at March 31, 2022.
Regulatory Filings
2022-04-21 English
Press Release
Regulatory Filings
2022-04-18 English
Lupin Receives Tentative Approval from U.S. FDA for Tenofovir Alafenamide Tablets.
Regulatory Filings
2022-04-18 English
Lupin Receives Approval from U.S. FDA for Desvenlafaxine Extended-Release Tablets 25 mg.
Regulatory Filings
2022-04-14 English
Press Release
Regulatory Filings
2022-04-14 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings
2022-04-12 English
Press Release
Regulatory Filings
2022-04-07 English
Lupin Launches Merzee® Capsules in the United States.
Regulatory Filings
2022-04-07 English
Compliances - Compliance certificate pursuant to Reg. 7(3) of SEBI (Listing obligations and Disclosure Requirements), 2015, for the year ended at March 31, 2022.
Regulatory Filings
2022-04-07 English
Press Release
Regulatory Filings
2022-04-07 English
Lupin Completes Acquisition of Brands from Anglo-French.
Regulatory Filings
2022-04-07 English
General updates
Regulatory Filings
2022-04-05 English
Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended at March 31, 2022.
Regulatory Filings
2022-04-05 English
General updates
Regulatory Filings
2022-04-05 English
U.S. FDA inspection at the Company''s Tarapur manufacturing facility.
Regulatory Filings
2022-04-05 English
Lupin Enters into Licensing Agreement with Alvion to market Cardiometabolic Drugs in the Southeast Asia region.
Regulatory Filings
2022-04-05 English
Press Release
Regulatory Filings
2022-04-05 English
General updates
Capital/Financing Update
2022-04-01 English
Lupin Limited has signed Definitive Agreement with Anglo-French Drugs & Industries Limited for acquiring a portfolio of brands (including all rights and interests associated with such products), ....
Capital/Financing Update
2022-04-01 English
General updates
Regulatory Filings
2022-03-31 English
U.S. FDA inspection of the Company''s Somerset, New Jersey (USA) facility. (Revised)
Regulatory Filings
2022-03-31 English
General updates
Regulatory Filings
2022-03-31 English
U.S. FDA inspection of the Company''s Somerset, New Jersey (USA) facility.
Regulatory Filings
2022-03-31 English
Loss of share certificate
Regulatory Filings
2022-03-25 English
Intimation of loss of share certificate by the share holder.
Regulatory Filings
2022-03-25 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-03-24 English
Disclosure in respect of allotment of 24230 shares under ESOP.
Regulatory Filings
2022-03-24 English
Press Release
Regulatory Filings
2022-03-24 English
Lupin Receives Approval from U.S. FDA for Sildenafil for Oral Suspension.
Regulatory Filings
2022-03-24 English
Lupin Receives Approval from U.S. FDA for Vigabatrin for Oral Solution USP.
Regulatory Filings
2022-03-11 English
Press Release
Regulatory Filings
2022-03-11 English
Lupin Launches its First Reference Laboratory in East India Establishing its Diagnostics Business in Kolkata.
Regulatory Filings
2022-03-10 English
Press Release
Regulatory Filings
2022-03-10 English
Lupin Teams up with Mary Kom to Raise Awareness Amongst Women on Cardiovascular Disease.
Regulatory Filings
2022-03-09 English
Press Release
Regulatory Filings
2022-03-09 English
Disclosure pursuant to grant of 8136 stock options under ESOP.
Regulatory Filings
2022-03-08 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-03-08 English
Press Release
Regulatory Filings
2022-03-07 English
Lupin signs on Mary Kom for its Women's Cardiovascular Health Awareness Initiative, Shakti.
Regulatory Filings
2022-03-07 English
Press Release
Regulatory Filings
2022-03-03 English
Lupin Receives Approval from U.S. FDA for Efinaconazole Topical Solution.
Regulatory Filings
2022-03-03 English
Press Release
Regulatory Filings
2022-03-01 English
Lupin Launches Sevelamer Hydrochloride Tablets in the United States.
Regulatory Filings
2022-03-01 English
Allotment of 66131 shares under ESOP.
Regulatory Filings
2022-02-24 English
ESOP/ESPS/SBEB Scheme
Regulatory Filings
2022-02-24 English
Press Release
Board/Management Information
2022-02-23 English
Lupin Announces Executive Leadership Change, Dr. Fabrice Egros to assume Corporate Development responsibilities as President, Corporate Development & Growth Markets.
Regulatory Filings
2022-02-23 English
Press Release
Regulatory Filings
2022-02-17 English
Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis.
Regulatory Filings
2022-02-17 English
Intimation regarding issuance of duplicate share certificate.
Regulatory Filings
2022-02-15 English
Loss of Share Certificates
Regulatory Filings
2022-02-15 English
Transcript of Q3 FY2022 Earnings Conference Call on February 4, 2022
Call Transcript
2022-02-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript
2022-02-13 English
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®.
Regulatory Filings
2022-02-09 English
Press Release
Regulatory Filings
2022-02-09 English
Press Release
Regulatory Filings
2022-02-08 English
Lupin Receives Approval from U.S. FDA for Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml.
Regulatory Filings
2022-02-08 English
Investor Presentation
Investor Presentation
2022-02-04 English
Investor Presentation Q3 FY2022.
Investor Presentation
2022-02-04 English
Press Release
Regulatory Filings
2022-02-03 English
Lupin Quarter 3 FY2022 Results.
Regulatory Filings
2022-02-03 English
Unaudited standalone and consolidated financial results for the quarter and nine-months ended December 31, 2021.
Regulatory Filings
2022-02-03 English
Financial Result Updates
Regulatory Filings
2022-02-03 English
Lupin and Axantia Enter into a License, Supply and Technology Sharing Agreement for Pegfilgrastim in the Middle East and North Africa.
Regulatory Filings
2022-02-01 English
Press Release
Capital/Financing Update
2022-02-01 English
Intimation regarding issuance of duplicate share certificate.
Regulatory Filings
2022-01-31 English
Intimation of loss of share certificate by shareholders.
Regulatory Filings
2022-01-31 English
Loss of Share Certificates
Regulatory Filings
2022-01-31 English
Loss of Share Certificates
Regulatory Filings
2022-01-31 English
Press Release
Regulatory Filings
2022-01-27 English
Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® (secnidazole) expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis.
Regulatory Filings
2022-01-27 English
Disclosure pursuant to allotment of 187787 equity shares under Lupin ESOP.
Share Issue/Capital Change
2022-01-27 English
ESOP/ESOS/ESPS
Share Issue/Capital Change
2022-01-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2022-01-25 English
Earnings Call for Quarter - III, FY 2022 is scheduled on Friday, February 4, 2022 at 18:30 hrs (IST).
Regulatory Filings
2022-01-25 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings
2022-01-19 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2022 ,inter alia, to consider and approve LUPIN LTD. has informed BSE that the ....
Regulatory Filings
2022-01-19 English
Lupin Signs First Partnership Agreement with Foncoo for China.
Capital/Financing Update
2022-01-19 English
Press Release
Capital/Financing Update
2022-01-19 English
Acquisition
Capital/Financing Update
2022-01-18 English
Acquisition of a portfolio of brands (including all rights and interests associated with such products) of Anglo-French Drugs & Industries Limited and its associates.
Capital/Financing Update
2022-01-18 English
Investor Presentation
Investor Presentation
2022-01-12 English
J.P Morgan Healthcare Conference Presentation
Investor Presentation
2022-01-12 English
Lupin launches Molnupiravir under the brand name Molnulup for the treatment of COVID-19 in adults in India.
Regulatory Filings
2022-01-07 English
Press Release
Regulatory Filings
2022-01-07 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2022-01-05 English
Certificate pursuant to Reg. 74(5) of SEBI (Depository and Participants) Regulations, 2018, for the quarter ended December 31, 2021.
Regulatory Filings
2022-01-05 English